JP2022172170A5 - - Google Patents

Download PDF

Info

Publication number
JP2022172170A5
JP2022172170A5 JP2022130651A JP2022130651A JP2022172170A5 JP 2022172170 A5 JP2022172170 A5 JP 2022172170A5 JP 2022130651 A JP2022130651 A JP 2022130651A JP 2022130651 A JP2022130651 A JP 2022130651A JP 2022172170 A5 JP2022172170 A5 JP 2022172170A5
Authority
JP
Japan
Prior art keywords
seq
antibody
ige
hlaaige
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022130651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022172170A (ja
JP7461420B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2018/012479 external-priority patent/WO2018129248A1/en
Application filed filed Critical
Publication of JP2022172170A publication Critical patent/JP2022172170A/ja
Publication of JP2022172170A5 publication Critical patent/JP2022172170A5/ja
Application granted granted Critical
Publication of JP7461420B2 publication Critical patent/JP7461420B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022130651A 2017-01-06 2022-08-18 治療抗IgE抗体並びにその方法及び組成物 Active JP7461420B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762443547P 2017-01-06 2017-01-06
US62/443,547 2017-01-06
PCT/US2018/012479 WO2018129248A1 (en) 2017-01-06 2018-01-05 Therapeutic anti-ige antibodies and methods and compositions thereof
JP2019537154A JP7128191B2 (ja) 2017-01-06 2018-01-05 治療抗IgE抗体並びにその方法及び組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019537154A Division JP7128191B2 (ja) 2017-01-06 2018-01-05 治療抗IgE抗体並びにその方法及び組成物

Publications (3)

Publication Number Publication Date
JP2022172170A JP2022172170A (ja) 2022-11-15
JP2022172170A5 true JP2022172170A5 (https=) 2023-04-13
JP7461420B2 JP7461420B2 (ja) 2024-04-03

Family

ID=62789396

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537154A Active JP7128191B2 (ja) 2017-01-06 2018-01-05 治療抗IgE抗体並びにその方法及び組成物
JP2022130651A Active JP7461420B2 (ja) 2017-01-06 2022-08-18 治療抗IgE抗体並びにその方法及び組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019537154A Active JP7128191B2 (ja) 2017-01-06 2018-01-05 治療抗IgE抗体並びにその方法及び組成物

Country Status (6)

Country Link
US (2) US11518818B2 (https=)
EP (1) EP3565587A4 (https=)
JP (2) JP7128191B2 (https=)
AU (1) AU2018205484B2 (https=)
CA (1) CA3049967C (https=)
WO (1) WO2018129248A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113474012B (zh) 2019-01-25 2023-09-08 湖南远泰生物技术有限公司 Epcam抗体和epcam-car-t细胞

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685939B2 (en) 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
CA2113813C (en) * 1991-08-14 2005-04-12 Paula M. Jardieu Immunoglobulin variants for specific fc epsilon receptors
HK1048127A1 (en) 2000-01-14 2003-03-21 Daiichi Pharmaceutical Co., Ltd. Novel peptide and screening method by using the same
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
SI2000481T1 (sl) * 2003-02-01 2016-08-31 Tanox, Inc. Anti-humana protitelesa IgE z visoko afiniteto
US20050169909A1 (en) * 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes
EP1718669A4 (en) * 2004-02-02 2007-10-10 Tanox Inc IDENTIFICATION OF NEW IGE EPITOPES
CN101203241B (zh) * 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
WO2008070593A2 (en) * 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
UY30994A1 (es) 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
CN101925611A (zh) * 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
US20130236467A1 (en) * 2010-11-24 2013-09-12 Jeremy Griggs Multispecific antigen binding proteins targeting hgf
KR20140119777A (ko) * 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
WO2013192594A2 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
WO2015195631A1 (en) 2014-06-17 2015-12-23 Academia Sinica HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CA3089260A1 (en) * 2018-01-22 2019-07-25 Jiangsu Hengrui Medicine Co., Ltd. Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof

Similar Documents

Publication Publication Date Title
US12180288B2 (en) Antibodies to canine interleukin-4 receptor alpha
US12410241B2 (en) Human monoclonal antibodies to enterovirus D68
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
US9926375B2 (en) Anti-endoglin antibodies and uses thereof
TW202110891A (zh) 抗psgl-1組合物及其用於調節骨髓細胞發炎表型之方法及用途
CA3067747A1 (en) Anti-allergen antibodies
WO2022117079A1 (zh) 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN104603150A (zh) 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体
JP7667773B2 (ja) カンジダ属に対する抗体およびその使用法
US20230063625A1 (en) Human antibodies to rift valley fever virus
JP7461420B2 (ja) 治療抗IgE抗体並びにその方法及び組成物
JP2022172170A5 (https=)
JP2021533806A (ja) 抗fcイプシロン−r1アルファ(fcer1a)抗体、fcer1aおよびcd3に結合する二重特異性抗原結合分子、ならびにそれらの使用
US20240026035A1 (en) Human ige monoclonal antibodies to antibodies to alpha-gal (galactose-a-1,3-galactose) and uses therefor
US11299535B2 (en) Human IgE antibodies binding to aspergillus allergens
Fick IgE and anti-IgE therapy in asthma and allergic disease
JP7754841B2 (ja) ヒト化抗ヒトcd89抗体及びその使用
JP2024105575A (ja) 特定の腸内細菌の抗体媒介中和による免疫疾患の治療
TW202413405A (zh) 抗體、其抗原結合片段及其藥物用途
BR112016029734B1 (pt) Anticorpo isolado ou fragmento de ligação ao antígeno deste e uso do mesmo, composição farmacêutica e método para detecção de níveis de expressão de il-21 em uma amostra